JKJunichi Kitanaka

Junichi Kitanaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Junichi Kitanaka has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Potential of Cannabidiol for the Treatment of Psychosis: Endocannabinoid Regulation of Serotonergic Neurotransmission via Serotonin 5-HT1A/2A Receptors

    by Kazutoshi Yonemura, Nobue Kitanaka, Kazuo Tomita, F. Scott Hall, Moe Matsuo, Kento Igarashi, Tomoaki Sato, George R. Uhl, Junichi Kitanaka

    Cannabis, widely used for both medical and non-medical purposes, primarily contains Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD). Δ9-THC is the main driver of cannabis abuse and of psychological and physical dependence, whereas CBD has limited abuse potential and is even being investigated as a treatment for cannabis use disorder and other conditions. This review aims to clarify how the molecular and receptor-level mechanisms of CBD, compared with Δ9-THC, shape its distinct therapeutic profile and low liability for addiction, thereby informing the safer clinical application of CBD-containing interventions to schizophrenia. CBD exerts sedative and therapeutic effects, including in treatment-resistant epilepsy, and acts in part via CB1 and CB2 receptors that also mediate Δ9-THC actions. While Δ9-THC activates these receptors as an agonist, triggering Gi-coupled signaling cascades such as MAPK pathways and suppressing presynaptic monoamine release, CBD functions as a non-competitive negative allosteric CB1 modulator and non-competitive antagonist of Δ9-THC. These distinct intracellular signaling mechanisms are considered to underlie the markedly different pharmacological profiles and abuse liabilities of Δ9-THC and CBD. CBD also engages multiple CNS targets beyond CB1 and CB2, including GPR55, TRPV1 and ENT1, which are implicated in anticonvulsant, anti-inflammatory, analgesic and neuroprotective actions. Although GPR55 pharmacology remains controversial and Δ9-THC shows inconsistent activity at this receptor, converging evidence indicates that CBD can antagonize CB1/CB2 and modulate atypical cannabinoid-sensitive proteins. Excessive activation of certain serotonin receptors, including 5-HT1A/2A, are thought to underlie some symptoms of psychosis. These diverse molecular actions are thought to underlie CBD’s broad therapeutic potential across seizures and other CNS disorders, providing a mechanistic rationale for exploring CBD as a treatment option for psychosis in schizophrenia and stimulant-induced psychotic states.

  • Open Access

    Daisaikoto restores mitochondrial function and suppresses inflammation induced by periodontal bacteria-derived lipopolysaccharides

    by Suzuka Tozawa, Kazuo Tomita, Kento Igarashi, Yoshikazu Kuwahara, Junichi Kitanaka, Nobue Kitanaka, Mehryar Habibi Roudkenar, Amaneh Mohammadi Roushandeh, Akihiro Kurimasa, Tomoaki Sato

  • Open Access

    Amoxicillin, a β-lactam antibiotic, enhances cisplatin sensitivity in cancer cells affecting mitochondria

    by Yoshino Takami, Kazuo Tomita, Kento Igarashi, Yoshikazu Kuwahara, Junichi Kitanaka, Nobue Kitanaka, Mehryar Habibi Roudkenar, Amaneh Mohammadi Roushandeh, Hideto Saijo, Akihiro Kurimasa, et al.


  • Open Access

    Silver Nanoparticles Reduce ACE2 Expression via Changing Mitochondrial Function in Human Fibroblast-Like Lung Cell and Periodontal Ligament Fibroblast Cells

    by Shosei Takahashi, Kazuo Tomita, Kento Igarashi, Yoshikazu Kuwahara, Junichi Kitanaka, Nobue Kitanaka, Koh-Ichi Tanaka, Akihiro Kurimasa, Yoshiaki Kamikawa, Tomoaki Sato


  • Protein phosphatase 2A inhibitors: a possible pharmacotherapy for benzodiazepine dependence

    by Chisa Kobayashi, Nobue Kitanaka, Masanori Nakai, F Scott Hall, Kazuo Tomita, Kento Igarashi, Tomoaki Sato, George R Uhl, Junichi Kitanaka

    Objectives: Benzodiazepines (BZDs) activate the γ-aminobutyric acid (GABA) subtype A (GABAA) receptors, and thus are widely used medicines for the treatment of anxiety and insomnia. For chronic use, tolerance to BZDs is a major problem. Patients with chronic insomnia that develop tolerance to BZDs lose therapeutic effects but also potentially suffer from BZD dependence resulting in BZD withdrawal. The development of such treatments is important for the appropriate use of BZDs. Methods: Research articles regarding investigation of BZD dependence were searched on PubMed, Embase, and Scopus databases using keywords “benzodiazepine”, “dependence”, “treatment”. Key findings: When BZDs are taken chronically, continuous GABAA binding results in up-regulation of α-amino-3-hydroxy-5-methyl-4-lisoxazolepropionic acid (AMPA) glutamate receptor function and release of brain-derived neurotrophic factor (BDNF). Released BDNF binds to its specific receptor tropomyosin-related kinase receptor B (TrkB). Enhanced BDNF-TrkB signaling activates protein phosphatase 2A (PP2A). Activated PP2A dephosphorylates GABAA receptors, resulting in the downregulation of the GABAA receptor function. Reduced GABAA receptor function augments long-term potentiation (LTP), AMPA-mediated glutamatergic neuroplasticity, by reducing LTP inhibition by GABAA receptor function. Augmented LTP enhances extreme anxiety, which leads to BZD dependence. Conclusion: Therefore, iInhibiting dephosphorylation of the GABAA receptor by PP2A, PP2A inhibitors could reduce LTP and anxiety, restoring BZD effectiveness and resulting in possible therapeutic effects for BZD dependence.


  • Role of glycogen synthase kinase-3β in dependence and abuse liability of alcohol

    by Masahiro Oka, Rui Yoshino, Nobue Kitanaka, F Scott Hall, George R Uhl, Junichi Kitanaka

    Alcohol is a major abused drug worldwide that contributes substantially to health and social problems. These problems result from acute alcohol overuse as well as chronic use, leading to alcohol use disorder (AUD). A major goal of this field is to establish a treatment for alcohol abuse and dependence in patients with AUD. The central molecular mechanisms of acute alcohol actions have been extensively investigated in rodent models. One of the central mechanisms that may be involved is glycogen synthase kinase-3β (GSK-3β) activity, a key enzyme involved in glycogen metabolism but which has crucial roles in numerous cellular processes. Although the exact mechanisms leading from acute alcohol actions to these chronic changes in GSK-3β function are not yet clear, GSK-3β nonetheless constitutes a potential therapeutic target for AUD by reducing its function using GSK-3β inhibitors. This review is focused on the correlation between GSK-3β activity and the degree of alcohol consumption. Research articles regarding investigation of effect of GSK-3β on alcohol consumption in rodents were searched on PubMed, Embase, and Scopus databases using keywords “glycogen synthase kinase,” “alcohol (or ethanol),” “intake (or consumption),” and evaluated by changes in ratios of pGSK-3βSer9/pGSK-3β. In animal experiments, GSK-3β activity decreases in the brain under forced and voluntary alcohol consumption while GSK-3β activity increases under alcohol-seeking behavior. Several pieces of evidence suggest that alterations in GSK-3β function are important mediators of chronic ethanol actions, including those related to alcohol dependence and the adverse effects of chronic ethanol exposure.


  • Open Access

    Kamishoyosan and Kamikihito protect against decreased KCC2 expression induced by the P. gingivalis lipopolysaccharide treatment in PC-12 cells and improve behavioral abnormalities in male mice

    by Kazuo Tomita, Yukiko Oohara, Kento Igarashi, Junichi Kitanaka, Nobue Kitanaka, Koh-Ichi Tanaka, Mehryar Habibi Roudkenar, Amaneh Mohammadi Roushandeh, Mitsutaka Sugimura, Tomoaki Sato


  • Are Histamine H3 Antagonists the Definitive Treatment for Acute Methamphetamine Intoxication?

    by Nobue Kitanaka, Junichi Kitanaka, F. Scott Hall, Koh-Ichi Tanaka, Kazuo Tomita, Kento Igarashi, Nobuyoshi Nishiyama, Tomoaki Sato, George R. Uhl

    Background: Methamphetamine (METH) is classified as a Schedule II stimulant drug under the United Nations Convention on Psychotropic Substances of 1971. METH and other amphetamine analogues (AMPHs) are powerful addictive drugs. Treatments are needed to treat the symptoms of METH addiction, chronic METH use, and acute METH overdose. No effective treatment for METH abuse has been established because alterations of brain functions under the excessive intake of abused drug intake are largely irreversible due in part to brain damage that occurs in the course of chronic METH use. Objective: Modulation of brain histamine neurotransmission is involved in several neuropsychiatric disorders, including substance use disorders. This review discusses the possible mechanisms underlying the therapeutic effects of histamine H3 receptor antagonists on symptoms of methamphetamine abuse. Conclusion: Treatment of mice with centrally acting histamine H3 receptor antagonists increases hypothalamic histamine contents and reduces high-dose METH effects while potentiating lowdose effects via histamine H1 receptors that bind released histamine. On the basis of experimental evidence, it is hypothesized that histamine H3 receptors may be an effective target for the treatment METH use disorder or other adverse effects of chronic METH use.


  • Neuroprotective effect of oxytocin on cognitive dysfunction, DNA damage, and intracellular chloride disturbance in young mice after cranial irradiation

    by Kento Igarashi, Haruki Iwai, Koh-Ichi Tanaka, Yoshikazu Kuwahara, Junichi Kitanaka, Nobue Kitanaka, Akihiro Kurimasa, Kazuo Tomita, Tomoaki Sato


  • Open Access

    Glycogen synthase kinase-3 inhibitors suppress morphine-induced Straub‘s tail reaction via a centrally acting mechanism

    by Junichi Kitanaka, Nobue Kitanaka, Kazuo Tomita, Kento Igarashi, Koh-Ichi Tanaka, Takuma Hashimoto, Kai Hirabayashi, Utau Horie, Kenta Iwasaki, Yumi Kawasaki, et al.

    Background: In the previous meeting, we have demonstrated that pretreatment with Glycogen synthase kinase-3 inhibitors (GSK3i) suppress morphine-induced Straub's tail reaction (STR). In this presentation, we investigated the GSK3i mechanism of action. Methods: In this presentation, expression levels of GSK3beta and phosphorylated GSK3beta (pGSK3betaser9) were examined in the region of the striatum and nucleus accumbens and in the cerebral cortex after systemic morphine. In constipated mice after morphine, the effect of GSK3i on gastrointestinal transit was also examined to reveal whether the action of GSK3i on morphine effects was central and/or peripheral. Results: Pretreatment of mice with SB216763 (5 mg/kg, s.c.) or AR-A014418 (3 mg/kg, s.c.) significantly inhibited morphine-induced STR. In the brain regions tested, expression levels of pGSK3betaser9 in mice after morphine were not altered in mice treated with GSK3i in combination with morphine. The pretreatment with Gsk3i did not improve constipation in morphine-injected mice. Conclusions: The inhibitory effect of GSK3i on morphine-induced STR might not depend on the blockade of GSK3 in terms of phosphorylation levels of pGSK3betaser9. The mechanism of action is likely to be central but not peripheral.